LLY
FY2026 Q1 · Calendar Q2 2026
Eli Lilly and Company
Q1 2026 marks a pivotal quarter for Eli Lilly. The FDA approval and commercial launch of Foundayo, the first oral GLP-1 therapy for obesity, adds a major new growth engine alongside continued Mounjaro and Zepbound dominance. Revenue grew 56% YoY to $19.8B, exceeding consensus by over $2B, while EPS of $8.55 surpassed estimates by 23%. Management raised full-year guidance to $82-$85B in revenue and $35.50-$37 in non-GAAP EPS, reflecting confidence that volume expansion can absorb U.S. pricing pressure. A session move of nearly 10% and subsequent drift of 18% suggest investors are pricing in sustained incretin franchise leadership. Execution on Foundayo scaling, manufacturing capacity buildout, and access program effectiveness will determine whether that trajectory holds.
EPS surprise+22.7%
Market move+9.8%
